5
Clinical Drug Investigation Prevalence of desloratadine slow metabolizer phenotype and food-dependent pharmacokinetics of desloratadine in healthy Chinese volunteers Ting Wang 1 , Kun Zhang 1 , Tingting Li 2 , Lin He 3 , Huiru Xie 1 , Xuehua Jiang 1 and Ling Wang 1 Corresponding author: Ling Wang. E-mail: [email protected] 1 Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of Drug Ministry of Education, West China School of Pharmacy, Sichuan University, China, 2 Pharmacy Department of People's Hospital of Xishuangbanna Dai Autonomous Prefecture, China, 3 Department of Pharmacy, Sichuan Provincial People’s Hospital, China Electronic Supplementary Material

Clinical Drug Investigation - Springer Static Content Server10.1007... ·  · 2015-10-08Clinical Drug Investigation ... 5.0e4 3.0e4 2.0e4 1.0e4 259.4 258.4 25 267.1 265 \ 294.2 292

Embed Size (px)

Citation preview

Clinical Drug Investigation

Prevalence of desloratadine slow metabolizer phenotype and

food-dependent pharmacokinetics of desloratadine in

healthy Chinese volunteers

Ting Wang1, Kun Zhang1, Tingting Li2, Lin He3, Huiru Xie1, Xuehua

Jiang1 and Ling Wang1

Corresponding author:

Ling Wang. E-mail: [email protected]

1 Department of Clinical Pharmacy and Pharmacy Administration, Key

Laboratory of Drug Ministry of Education, West China School of

Pharmacy, Sichuan University, China,

2 Pharmacy Department of People's Hospital of Xishuangbanna Dai

Autonomous Prefecture, China,

3 Department of Pharmacy, Sichuan Provincial People’s Hospital,

China

Electronic Supplementary Material

Supplemental Figure Legends

Fig. S1. Chemical structures with fragmentation and product ion spectrum of [M + H]+ of desloratadine

(a), 3-OH-desloratadine (b) and diphenhydramine (c) (IS).

Fig. S2. MRM chromatogram of blank plasma (a); blank plasma spiked with desloratadine and

3-OH-desloratadine with their IS (10 ng/mL) at the LLOQ (0.05 ng/mL) (b); a plasma sample obtained

from a subject at 1.5 h post dosing (c).

Fig. S3. Individual pharmacokinetic parameters for desloratadine (a, b) and 3-OH-desloratadine (c, d)

following oral administration of 5 mg desloratadine tablet.

Fig. S1

Fig. S2

Fig. S3